Atypical p38 Kinase Signaling in Retinal Vascular Damage and Recovery
Lillian Schulz, Abby Young, Fang LiuiD, Sanjana Gattineni, Sneha Ghosh, Eugene F. DouglassiD, Heike KroegeriD, S. Priya NarayananiD, Neil Justin GrimseyiD
Abstract
Despite the life-changing impact of anti-VEGF therapies, vascular retinopathies continue to affect millions of patients worldwide. To better understand disease progression, it is essential to define alternative mechanisms that contribute to retinal vascular dysregulation. Mitogen-activated protein kinase (MAPK) p38 plays a significant role in regulating vascular homeostasis, angiogenesis, and retinal disease progression, yet effective therapeutic targeting remains elusive. An alternative atypical p38 signaling pathway is mediated by interaction with the adaptor protein TGF-beta activated kinase 1, binding protein 1 (TAB1). Atypical p38 can be activated by ischemia or by inflammatory G protein-coupled receptors (GPCRs) to regulate inflammation and vascular homeostasis. However, atypical signaling has not been investigated in the context of vascular retinopathies, specifically oxygen-induced retinopathy (OIR). Here, we utilized a genetic knock-in mouse to block atypical p38 activity (Tab1KI) to explore retinal damage during OIR. We report that Tab1KI mice display significantly reduced vaso-obliteration and limited neovascularization relative to wild-type C57BL6 controls. Retinal RNAseq analysis revealed distinct transcriptional regulation in the Tab1KI mouse. Suppression of atypical p38 reduced Mef2c signaling, which in turn enhanced microglial activation and inflammation. Despite the upregulation of proangiogenic markers, the increase in endothelial markers does not correlate with the dysregulated growth of blood vessels. Instead, Mef2c suppression reduces pathological angiogenesis, while increasing physiological vascular regrowth. The combined data suggest that the selective inhibition of atypical p38 signaling could block the enhanced pathogenic neovascular tuft formation without impacting blood vessel repair. Further investigation will clarify how atypical p38 controls neovascular responses, potentially revealing new treatment strategies for vascular retinopathies. NEW AND NOTEWORTHYMAPK p38 drives ocular injury and inflammation, but the contribution of Tab1-dependent atypical p38 in retinal injury has not been investigated. Using a mouse genetic knock-in model to block atypical p38 during oxygen-induced retinal injury, we show that atypical p38 enhances vascular damage and neovascular tufting. Blockade of atypical p38 protects mice from retinal vascular damage.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- FWCI
- 1.72
- Field percentile
- top 15%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- TAK1 blockade as a therapy for retinal neovascularization
F.-L. Lin, J.-H. Wang, … G.-S. Liu·bioRxiv·Jan 29, 2021
- Targeting endothelial ERG to mitigate vascular regression and neuronal ischemia in retinopathies
Eric Ma, Christopher M. Schafer, … Courtney T. Griffin·Proceedings of the National Academy of SciencesPeer-reviewed·Sep 23, 2025
- MicroRNA-143 plays a protective role in ischemia-induced retinal neovascularization
Jiang-Hui Wang, Yu-Fan Chuang, … Guei‐Sheung Liu·Nucleic Acid TherapeuticsPeer-reviewed·Apr 1, 2022
- Therapeutic activation of endothelial sphingosine 1-phosphate receptor-1 by chaperone-bound S1P suppresses proliferative retinal vasculopathy
C. Niaudet, B. Jung, … T. Hla·bioRxiv·Jun 14, 2022
- ASK1/p38-mediated NLRP3 inflammasome signaling pathway contributed to aberrant retinal angiogenesis in diabetic retinopathy
- eNOS-induced vascular barrier disruption in retinopathy by c-Src activation and tyrosine phosphorylation of VE-cadherin
T. Ninchoji, D. T. Love, … L. Claesson-Welsh·bioRxiv·Nov 24, 2020